() has completed a successful pilot study of its final dose form for its proprietary cannabinoid medicines.
Through its research, AusCann has developed a unique effective stable oral dose form which provides consistent and stable dosages of the active cannabinoids.
The study was carried out over the past ten months to be ready for the release of AusCann’s first cannabinoid medicines in first half of 2019.
READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia
AusCann’s managing director Elaine Darby said: “AusCann has developed something truly unique in the world of cannabinoid medicines.
“Delivery of consistent and stable products has been an issue that plagues the cannabis medicine industry.
“This new hard capsule will be a game changer for doctors and patients as it is easy to use and will give consistent treatment outcomes every time.
“We are thrilled with the success of this study and look forward to releasing these new pharmaceuticals next year.”
Well-funded to deliver on strategy
Following a placement and subsequent share purchase plan last month, AusCann is well-funded to deliver on its path of developing safe, efficacious, clinically-validated and cost-effective cannabinoid medicines.
Patent lodged for unique capsule dose
Currently, medicinal cannabis is typically administered via oral liquids, liquid sprays, hard or soft-shell gelatin capsules containing cannabinoids dissolved in oils, or inhalation of dried material or extracts.
The main drawback to these formulations is the stability of the active cannabinoids which results in variability in the composition and the efficacy of the formulations.
